Figure 1.

High-Throughput In Vitro and In Silico Screenings Identify Drugs that Modulate ACE2 Expression in hESC-Derived Cardiomyocytes

(A and B) High-throughput screening of Selleckchem FDA-approved drug library identifies drugs that increase and decrease ACE2 expression in hESC-derived cardiomyocytes.

(C) Representative immunofluorescent images of cells treated with vehicle, vincristine, and dronedarone at 1 μM. Scale bar: 200 μm.

(D and E) Dose response of hits that (D) decreased and (E) increased ACE2 expression in hESC-derived cardiomyocytes culture.

(F) Two-dimensional visualization of molecular features (Morgan fingerprints) for the in vitro and in silico tested compounds using UMAP. For the ZINC15 library, the points are sub-sampled by a factor of 10³.

(G) UMAP visualization of the in vitro (labeled) and in silico (unlabeled) hit compounds. Also shown are the K-means cluster memberships based on their Morgan fingerprints.

(H) Dose response analysis of selected in silico hit compounds in hESC-derived cardiac cells. Data are represented as mean ± SEM.

(I) Effect of selected in silico hit compounds on ACE2 expression in human primary alveolar epithelial cells. Data are represented as mean ± SEM.

^∗p value < 0.05, ^∗∗p value < 0.01, ^∗∗∗p value < 0.001. See also Figure S1 and Table S1.